Amarin Corp Plc (AMRN)

[KCSVEN]

Except there are more questions going in

The only potential negative in the data for inclisiran comes from an exploratory endpoint that looked at adverse cardiovascular events. Numerically, more patients in the inclisiran group had a heart attack or stroke or died of cardiovascular causes. The differences between the arms are small but may raise doubts about the improved cardiovascular outcomes seen in the earlier phase 3 trial.